BofA Securities reduced its price objective for GoodRx to $2.60 from $3.00 and reiterated an Underperform rating, reflecting a 4.0x calendar-year 2026 EBITDA multiple versus 4.5x previously. The firm cited persistent headwinds in the pharmacy ecosystem, including location closures at major retail chains such as CVS, Rite Aid and Walgreens, along with reimbursement changes that weighed on GoodRx’s core prescription transaction business during 2025. Recent shifts in pharmacy benefit manager contracts with plan sponsors, which may accelerate net pricing pressures at the pharmacy counter, were also flagged as a source of added uncertainty for GoodRx’s primary revenue stream.

GoodRx announced the launch of the newly FDA-approved Wegovy® pill (oral semaglutide) at a cash price of $149 per month, available at more than 70,000 pharmacies nationwide. This expansion builds on GoodRx’s strategy to diversify revenue beyond PBM-linked transactions, offering consumers a streamlined path to prescription savings. Later this quarter, users will gain access to licensed healthcare providers through the GoodRx for Weight platform to evaluate treatment options and facilitate prescription issuance.